BLCO Stock Overview
Operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BLCO from our risk checks.
Bausch + Lomb Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.55 |
| 52 Week High | US$17.85 |
| 52 Week Low | US$13.16 |
| Beta | 0.46 |
| 11 Month Change | -2.81% |
| 3 Month Change | 4.08% |
| 1 Year Change | -11.60% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.25% |
Recent News & Updates
Recent updates
Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?
Sep 13
Little Excitement Around Bausch + Lomb Corporation's (NYSE:BLCO) Revenues
Jun 22Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner
May 24Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 30Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?
Mar 25Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)
Feb 19Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound
Jan 31Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price
Jan 14Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)
Nov 08Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S
Nov 03An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued
Aug 15Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease
Aug 09These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong
May 09Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate
Mar 28Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M
Feb 22Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne
Feb 01Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect
Jan 24Bausch + Lomb acquires AcuFocus for cataract lens
Jan 17Shareholder Returns
| BLCO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.3% | 2.5% | 4.2% |
| 1Y | -11.6% | 17.2% | 24.4% |
Return vs Industry: BLCO underperformed the US Medical Equipment industry which returned 17.2% over the past year.
Return vs Market: BLCO underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| BLCO volatility | |
|---|---|
| BLCO Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BLCO has not had significant price volatility in the past 3 months.
Volatility Over Time: BLCO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1853 | 13,300 | Brent Saunders | www.bausch.com |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Bausch + Lomb Corporation Fundamentals Summary
| BLCO fundamental statistics | |
|---|---|
| Market cap | US$5.47b |
| Earnings (TTM) | -US$456.00m |
| Revenue (TTM) | US$4.50b |
1.2x
P/S Ratio-12.0x
P/E RatioIs BLCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLCO income statement (TTM) | |
|---|---|
| Revenue | US$4.50b |
| Cost of Revenue | US$1.76b |
| Gross Profit | US$2.74b |
| Other Expenses | US$3.19b |
| Earnings | -US$456.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 60.85% |
| Net Profit Margin | -10.14% |
| Debt/Equity Ratio | 70.4% |
How did BLCO perform over the long term?
See historical performance and comparison